Adaptive Biotechnologies Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00650F1093
USD
17.46
-1.23 (-6.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Adaptive Biotechnologies Corp.
ADMA Biologics, Inc.
Prime Medicine, Inc.
Inhibrx, Inc.
Dianthus Therapeutics, Inc.
Immatics NV
Kymera Therapeutics, Inc.
Rayzebio, Inc.
Cogent Biosciences, Inc.
Apogee Therapeutics, Inc.
Axcella Health, Inc.
Why is Adaptive Biotechnologies Corp. ?
1
With a growth in Net Sales of 12.27%, the company declared Outstanding results in Jun 25
  • The company has declared positive results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD -80.46 MM
  • NET SALES(Q) Highest at USD 58.88 MM
  • RAW MATERIAL COST(Y) Fallen by -32.22% (YoY)
2
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Market Beating performance in long term as well as near term
  • Along with generating 264.16% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Adaptive Biotechnologies Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Adaptive Biotechnologies Corp. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Adaptive Biotechnologies Corp.
177.14%
6.27
76.92%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
17.36%
EBIT Growth (5y)
-1.27%
EBIT to Interest (avg)
-88.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.45
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.05
EV to EBIT
-10.97
EV to EBITDA
-12.74
EV to Capital Employed
10.52
EV to Sales
7.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-95.89%
ROE (Latest)
-70.23%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -80.46 MM

NET SALES(Q)

Highest at USD 58.88 MM

RAW MATERIAL COST(Y)

Fallen by -32.22% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 7.46 times

OPERATING PROFIT(Q)

Highest at USD -20.53 MM

OPERATING PROFIT MARGIN(Q)

Highest at -34.87 %

PRE-TAX PROFIT(Q)

Highest at USD -25.59 MM

NET PROFIT(Q)

Highest at USD -25.61 MM

EPS(Q)

Highest at USD -0.17

-3What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at 11.16 %

CASH AND EQV(HY)

Lowest at USD 391.3 MM

Here's what is working for Adaptive Biotechnologies Corp.
Operating Cash Flow
Highest at USD -80.46 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
Highest at USD 58.88 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Net Sales
At USD 58.88 MM has Grown at 24.27%
over average net sales of the previous four periods of USD 47.38 MM
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD -20.53 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at -34.87 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD -25.59 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -25.61 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.17
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Inventory Turnover Ratio
Highest at 7.46 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -32.22% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Adaptive Biotechnologies Corp.
Debt-Equity Ratio
Highest at 11.16 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Cash and Eqv
Lowest at USD 391.3 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents